EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 38 / Numéro 6-7 (Juin–Juillet 2022) Med Sci (Paris), 38 6-7 (2022) 553-561 Références
Open Access
Numéro
Med Sci (Paris)
Volume 38, Numéro 6-7, Juin–Juillet 2022
Page(s) 553 - 561
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2022081
Publié en ligne 29 juin 2022
  1. Zhang SY, Jouanguy E, Zhang Q, et al. Human inborn errors of immunity to infection affecting cells other than leukocytes: from the immune system to the whole organism. Curr Opin Immunol 2019 ; 59 : 88–100. [CrossRef] [PubMed] [Google Scholar]
  2. Dawson R.Cellular Inclusions in Cerebral Lesions of Lethargic Encephalitis. Am J Pathol 1933 ; 9 : 7–163. [Google Scholar]
  3. van Bogaert L.Une leuco-encéphalite sclérosante subaiguë. J Neurol Neurosurg Psychiatry 1945 ; 8 : 101–120. [CrossRef] [PubMed] [Google Scholar]
  4. Bouteille M, Fontaine C, Vedrenne CSur un cas d’encephalite subaiguë à inclusions. Etude anatomoclinique et ultrastructurale. Rev neurol 1965 ; 113 : 454–458. [Google Scholar]
  5. Connolly JH, Allen IV, Hurwitz LJ, Millar JHSubacute sclerosing panencephalitis. Clinical, pathological, epidemiological, and virological findings in three patients. Q J Med 1968 ; 37 : 625–644. [PubMed] [Google Scholar]
  6. Baublis JV, Payne FEMeasles antigen and syncytium formtion in brain cell cultures from subacute sclerosing panencephalitis (SSPE). Proc Soc Exp Biol Med 1968 ; 129 : 593–597. [CrossRef] [Google Scholar]
  7. Satoh Y, Higuchi K, Nishikawa D, et al. M protein of subacute sclerosing panencephalitis virus, synergistically with the F protein, plays a crucial role in viral neuropathogenicity. J Gen Virol 2021; 102 : 001682. [CrossRef] [Google Scholar]
  8. Ayata M, Takeuchi K, Takeda M, et al. The F gene of the Osaka-2 strain of measles virus derived from a case of subacute sclerosing panencephalitis is a major determinant of neurovirulence. J Virol 2010 ; 84 : 11189–11199. [CrossRef] [PubMed] [Google Scholar]
  9. Lebon P, Gelot A, Zhang SY, et al. Measles Sclerosing Subacute PanEncephalitis (SSPE), an intriguing and ever-present disease: Data, assumptions and new perspectives. Rev Neurol (Paris) 2021; 177 : 1059–68. [CrossRef] [PubMed] [Google Scholar]
  10. Mathieu C, Bovier FT, Ferren M, et al. Molecular Features of the Measles Virus Viral Fusion Complex That Favor Infection and Spread in the Brain. mBio 2021; 12 : e0079921. [CrossRef] [PubMed] [Google Scholar]
  11. Gutierrez J, Issacson R, Koppel BSSubacute sclerosing panencephalitis: an update. Dev Med Child Neurol 2010 ; 52 : 901–907. [CrossRef] [PubMed] [Google Scholar]
  12. Saha V, John TJ, Mukundan P, et al. High incidence of subacute sclerosing panencephalitis in south India. Epidemiol Infect 1990 ; 104 : 151–156. [CrossRef] [PubMed] [Google Scholar]
  13. Lucas KM, Sanders RC, Rongap A, et al. Subacute sclerosing panencephalitis (SSPE) in Papua New Guinea: a high incidence in young children. Epidemiol Infect 1992 ; 108 : 547–553. [CrossRef] [PubMed] [Google Scholar]
  14. Mekki M, Eley B, Hardie D, Wilmshurst JMSubacute sclerosing panencephalitis: clinical phenotype, epidemiology, and preventive interventions. Dev Med Child Neurol 2019 ; 61 : 1139–1144. [CrossRef] [PubMed] [Google Scholar]
  15. Rebière I, Drucker JEpidemiological surveillance of measles in France. Santé 1994 ; 4 : 189–190. [Google Scholar]
  16. Mitus MA, Holloway HA, Evans AE, Enders JFAttenuated measles vaccine in children with acute leukemia. Am J Dis Child 1962 ; 103 : 413–418. [PubMed] [Google Scholar]
  17. Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999 ; 29 : 855–861. [CrossRef] [PubMed] [Google Scholar]
  18. Duncan CJ, Mohamad SM, Young DF, et al. Human IFNAR2 deficiency: Lessons for antiviral immunity. Sci Transl Med 2015 30; 7 : 307ra154. [Google Scholar]
  19. Aicardi J, Goutieres F, Arsenio-Nunes ML, Lebon PAcute measles encephalitis in children with immunosuppression. Pediatrics 1977 ; 59 : 232–239. [CrossRef] [PubMed] [Google Scholar]
  20. Prashanth LK, Taly AB, Sinha S, Ravi VSubacute sclerosing panencephalitis (SSPE): an insight into the diagnostic errors from a tertiary care university hospital. J Child Neurol 2007 ; 22 : 683–688. [CrossRef] [PubMed] [Google Scholar]
  21. Bonifas-Galup P, Hamano KC, Sebrosa J, et al. Different clinical and electroencephalographic aspects of subacute sclerosing panencephalitis (SSPE). A propos of 51 cases. Rev Electroencephalogr Neurophysiol Clin 1983 ; 13 : 224–231. [CrossRef] [PubMed] [Google Scholar]
  22. Chabrol B, Mancini J, Dulac O, et al. Neurologie pédiatrique 2010 ; 3third editionParisM-S Flammarion Lavoisierp403–p494. [Google Scholar]
  23. Häusler M, Aksoy A, Alber M, et al. A Multinational Survey on Actual Diagnostics and Treatment of Subacute Sclerosing Panencephalitis. Neuropediatrics 2015 ; 46 : 377–384. [CrossRef] [PubMed] [Google Scholar]
  24. Radermecker J.Clinical and electroencephalographic aspects of subacute sclerosing leukoencephalitis. Rev Neurol (Paris) 1951 ; 84 : 680–684. [PubMed] [Google Scholar]
  25. Prasad C, Netravathi M, Kulanthaivelu K, et al. Subacute Sclerosing Panencephalitis: Restricted Diffusion and Clinical Evolution. Neurol India 2022; 70 : 275–80. [PubMed] [Google Scholar]
  26. Lebon P, Chany C, Turpin JCDemonstration of antibodies precipitating an antigen of Carrés disease virus in the serum of patients with LESS. C R, Acad Hebd Seances Acad Sci D 1972 ; 274 : 1757–1760. [Google Scholar]
  27. Ziola B, Salmi A, Panelius M, Halonen P. Measles virus-specific IgM antibodies and IgM-class rheumatoid factor in serum and cerebrospinal fluid of subacute sclerosing panencephalitis patients. Clin Immunol Immunopathol 1979 ; 13 : 462–474. [CrossRef] [PubMed] [Google Scholar]
  28. Loirat C, Danon F, Broyer MSubacute sclerosing panencephalitis appearing during nephrotic syndrome treated with immunosuppressive agents. Arch Fr Pediatr 1971 ; 28 : 1083–1091. [PubMed] [Google Scholar]
  29. Lebon P, Freymuth FVirus de la rougeole : immunodépression, diagnostic. Médecine thérapeutique/pédiatrie 2010 ; 13 : 343–352. [Google Scholar]
  30. Pons JC, Lebon P, Frydman R, Delfraissy JFPharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther 1995 ; 10 : 7–10. [CrossRef] [PubMed] [Google Scholar]
  31. Sawaishi Y, Abe T, Yano T, Ishikawa K, Takada GSSPE following neonatal measles infection. Pediatr Neurol 1999 ; 20 : 63–65. [CrossRef] [PubMed] [Google Scholar]
  32. Krivine A, Force G, Servan J, et al. Measuring HIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: insights into the pathogenesis of AIDS Dementia Complex. J Neurovirol 1999 ; 5 : 500–506. [CrossRef] [PubMed] [Google Scholar]
  33. Cavlek TV, Sternak SL, Kaic B, et al. Subacute sclerosing panencephalitis in Croatia (1994–2004). Acta Microbiol Immunol Hung 2007 ; 54 : 57–63. [CrossRef] [PubMed] [Google Scholar]
  34. Comert S, Vitrinel A, Alper Gursu H, et al. Subacute sclerosing panencephalitis presenting as acute disseminated encephalomyelitis. Indian J Pediatr 2006 ; 73 : 1119–1121. [CrossRef] [PubMed] [Google Scholar]
  35. Lackmann GM, Hannen M, Madjlessi F, et al. Rapid progressive subacute sclerosing panencephalitis in a 2-year-old child with congenital athyreosis. Clin Infect Dis 2000 ; 31 : 196–199. [CrossRef] [PubMed] [Google Scholar]
  36. Oldstone MB, Dales S, Tishon A, et al. Role for dual viral hits in causation of subacute sclerosing panencephalitis. J Exp Med 2005 ; 202 : 1185–1190. [CrossRef] [PubMed] [Google Scholar]
  37. Lyon G, Ponsot G, Lebon PAcute measles encephalitis of the delayed type. Ann Neurol 1977 ; 2 : 322–327. [CrossRef] [PubMed] [Google Scholar]
  38. Ponsot G, Lebon P, Lyon GAcute delayed measles encephalitis. J Neurol Sci 1978 ; 39 : 99–109. [CrossRef] [PubMed] [Google Scholar]
  39. Aulakh R, Tiwari ASubacute sclerosing panencephalitis in a toddler: changing epidemiological trends. Case Rep Pediatr 2013 ; 2013 : 341462. [PubMed] [Google Scholar]
  40. Coulter JB, Balch N, Best PVSubacute sclerosing panencephalitis after drug-induced immunosuppression. Arch Dis Child 1979 ; 54 : 640–642. [CrossRef] [PubMed] [Google Scholar]
  41. Fukuya H, Ohfu M, Tomoda Y, et al. A case of subacute sclerosing panencephalitis developing 8 years after immunosuppressive treatment for acute lymphocytic leukemia. No To Hattatsu 1992 ; 24 : 60–64. [PubMed] [Google Scholar]
  42. Garg RK, Sharma PK, Kumar N, Pandey S. Subacute Sclerosing Panencephalitis in Older Adulthood. Tremor Other Hyperkinet Mov (N Y) 2019; 9. [Google Scholar]
  43. Klenerman P, Hengartner H, Zinkernagel RMA non-retroviral RNA virus persists in DNA form. Nature 1997 ; 390 : 298. [CrossRef] [PubMed] [Google Scholar]
  44. Moulias RL, Reinert P, Goust JMImmunologic abnormalities in subacute sclerosing panencephalitis. N Engl J Med 1971 ; 285 : 1090. [PubMed] [Google Scholar]
  45. Lebon P, Schuller E, JD Degos JD, et al. CSF alpha and gamma interferons in acute and subacute and multiple sclerosis: comparative study. Cellular and humoral immunological components of cerebrospinal fluid in multiple sclerosis. In: Cellular and Humoral immunological components of cerebrospinal fluid in multiple sclerosis. Ed. A Lowenthal and J. Raus. Paris: Plenum Press, 1986 : 429–436. [Google Scholar]
  46. Gadoth N, Kott E, Levin S, Hahn TThe interferon system in subacute sclerosing panencephalitis and its response to isoprinosine. Brain Dev 1989 ; 11 : 308–312. [CrossRef] [PubMed] [Google Scholar]
  47. Lebon P, Boutin B, Dulac O, et al. Interferon gamma in acute and subacute encephalitis. Br Med J 1988 ; 296 : 9–11. [CrossRef] [PubMed] [Google Scholar]
  48. Schuller E, Delasnerie N, Lebon PDNA and RNA antibodies in serum and CSF of multiple sclerosis and subacute sclerosing panencephalitis patients. J Neurol Sci 1978 ; 37 : 31–36. [CrossRef] [PubMed] [Google Scholar]
  49. Joncas JH, Robillard LR, Boudreault A, et al. Letter: Interferon in serum and cerebrospinal fluid in subacute sclerosing panencephalitis. Can Med Assoc J 1976 ; 115 : 309. [PubMed] [Google Scholar]
  50. Ogata S, Ogata A, Schneider-Schaulies S, Schneider-Schaulies JExpression of the interferon-alpha/beta-inducible MxA protein in brain lesions of subacute sclerosing panencephalitis. J Neurol Sci 2004 ; 223 : 113–119. [CrossRef] [PubMed] [Google Scholar]
  51. Lyon G, Griscelli C, Fernandez-Alvarez E, et al. Chronic progressive encephalitis in children with x-linked hypogammaglobulinemia. Neuropédiatrie 1980 ; 11 : 57–71. [CrossRef] [Google Scholar]
  52. Hara T, Yamashita S, Aiba H, et al. Measles virus-specific T helper 1/T helper 2-cytokine production in subacute sclerosing panencephalitis. J Neurovirol 2000 ; 6 : 121–126. [CrossRef] [PubMed] [Google Scholar]
  53. Dhib-Jalbut S, Jacobson S, McFarlin DE, McFarland HFImpaired measles-specific cytotoxic T-cell response in subacute sclerosing panencephalitis. Ann N Y Acad Sci 1988 ; 540 : 645–648. [CrossRef] [PubMed] [Google Scholar]
  54. Memon SA, Afzal SS, Tukruna A, et al. Trends and Treatment of Sub-Acute Sclerosing Panencephalitis: An Updated Review. Glob Pediatr Health 2021; 8 : 2333794X211065330. [PubMed] [Google Scholar]
  55. Guler S, Kucukkoc M, Iscan APrognosis and demographic characteristics of SSPE patients in Istanbul. Turkey. Brain Dev 2015 ; 37 : 612–617. [CrossRef] [Google Scholar]
  56. Griffin DEImmune responses to RNA-virus infections of the CNS. Nat Rev Immunol 2003 ; 3 : 493–502. [CrossRef] [PubMed] [Google Scholar]
  57. Hernandez N, Bucciol G, Moens L, et al. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J Exp Med 2019 ; 216 : 2057–2070. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.